PLATFORM
Treatment Modalities with Universal Applicability
TRANSMAB® Platform
Conventional antibodies cannot normally enter the brain due to physical barrier known as the blood-brain barrier (BBB).
TRANSMAB® platform transforms conventional antibodies into novel, next-generation BBB-penetrating antibodies by fusing multiple copies of de novo peptides selected from the TRANSPEP® library using our proprietary deep learning model.
TRANSMAB® antibodies are specifically designed to bind to the distinctive dense clustering patterns of transferrin receptors expressed on brain capillaries, enabling them to effectively penetrate throughout the brain parenchyma.
TRANSPEP® Library
We harness the synergy of de novo design, structural biology, and directed evolution approaches to craft hypercompact and stable protein binders targeting the transferrin receptor.
TRANSPEP® library consists of de novo peptides with diverse affinities and properties for multivalent fusion with a conventional antibody, ensuring optimized avidity control.
Super-Selective Binding
TRANSMAB® antibodies selectively bind to the dense clustering of transferrin receptor (TfR) on brain vessels, while avoiding other TfR-expressing tissues, such as immature red blood cells, which have a relatively low surface receptor concentration.
Reticulocytes
Brain Vessels
Brain Vessels
Reticulocytes
Brain Vessels
Reticulocytes
Superior Brain Penetration
TRANSMAB® leverages TfR, which is densely present on brain microvessels throughout the entire brain – a common feature across difference species, including humans. This makes TRANSMAB® an ideal strategy for developing therapeutic antibodies targeting brain diseases.
Key properties of TRANSMAB® include:
-
High brain bioavailability
-
Brain-selective biodistribution
-
Unaltered systemic pharmacokinetics
-
No TfR-related side effects
-
Cross-species reactivity
Superior
Pharmacokinetics Profile
Brain PK profiles in AD mice
Plasma PK profiles in AD mice
TRANSMAB® offers a distinct competitive advantage compared to other blood-brain barrier (BBB) platforms that bind to TfR in a 1:1 manner. TRANSMAB® leverages the unique local TfR density specific to brain capillaries, enabling a switch-like binding mechanism, effectively minimizing off-target binding and associated side effects.
The superior pharmacokinetic profiles of TRANSMAB®, marked by high brain bioavailability without compromising the systemic PK, establish a groundbreaking standard for antibody development in brain-related diseases.
